1. Science
  2. Biology
  3. datalsituation the clinician for an acute myeloid leukemia aml patient...

Question: datalsituation the clinician for an acute myeloid leukemia aml patient...

Question details

DatalSituation The clinician for an acute myeloid leukemia (AML) patient is considering prescribing therapy involving sorafenib and quizartinib. The following protein fragment sequence has been obtained from a sample from the patient. nvltfedllc fayqvakgme flefkscvhr dlaarnvlvt hgkvvkicdf glaraimsds nyvvrgnarl pvkwmapesl fegiytiksd vwsygillwe ifslgvnpyp gipvdanfyk ligngfkmda pfyateeiyi imascwafdskrpsfpnit stigcqlad Questions: (2 points each) a. What is the gene name of the protein from which the fragment is derived? b. What is the complete sequence of the protein in fasta format? c. What mutation has occurred in the protein? - give the change and the position relative to the complete protein d. The protein is a protein kinase which means that it adds a phosphate group to another protein to change its function. This is useful in the process of passing cellular signals, for phosphate to? (Hint it is in the name of the type of kinase family that the protein belongs to) What can quizartinib do to the activity of this protein? (Hint use DrugBank...) e. Should the patient undergo the considered therapy? -why or why not and give at least one journal reference for your answer.

Solution by an expert tutor
Blurred Solution
This question has been solved
Subscribe to see this solution